{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT03424629",
      "OrgStudyIdInfo": {
        "OrgStudyId": "TianjinEverUnion"
      },
      "Organization": {
        "OrgFullName": "Tianjin Ever Union Biotechnology Co., Ltd.",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "Safety and Efficacy of UC-MSCs in Patients With Plaque Psoriasis",
      "OfficialTitle": "A Randomized, Positive Controlled Trial That Assess the Safety And Efficacy of Umbilical Cord-Derived Mesenchymal Stem Cells in Moderate and Severe Plaque Psoriasis Patients"
    },
    "StatusModule": {
      "StatusVerifiedDate": "December 2017",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Not yet recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "June 1, 2018",
        "StartDateType": "Anticipated"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "September 30, 2018",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 31, 2019",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "December 27, 2017",
      "StudyFirstSubmitQCDate": "January 31, 2018",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "February 7, 2018",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "April 18, 2018",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "April 20, 2018",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Tianjin Ever Union Biotechnology Co., Ltd.",
        "LeadSponsorClass": "INDUSTRY"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "This is a study in patients with moderate to severe chronic plaque psoriasis.All the participants will be randomized into three groups, high-dose UC-MSCs, low-dose UC-MSCs, or methotrexate group.This study is designed to prove that UC-MSCs is safe and effective.",
      "DetailedDescription": "Psoriasis is a chronic, incurable, immune-mediated dermatological disease, and it is considered that immune system dysregulation is the important cause of the disease.Umbilical cord derived mesenchymal stem cells (UC-MSCs) have be proven safe and effective for the treatment of various intractable autoimmune and inflammatory disorders because of their distinct immunomodulatory properties.\n\nPatients will be randomized into three groups.In one group patients will be treated with 1x10^6 cells/kg in 0,1,2,3,5,7 week, in the second group patients will be treated with 3x10^6 cells/kg in 0,1,2,3,5,7 week,in the third group patients will be treated with 5-25mg Methotrexate from 0 to 15 week In this study, researchers will determine the safety of UC-MSCs that a patient can tolerate without causing side effects. Moreover researchers will also be assess the efficacy and sustainability of UC-MSCs in 52 weeks."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Moderate and Severe Plaque Psoriasis"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "psoriasis",
          "UC-MSCs"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Crossover Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "57",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Low-Dose UC-MSCs",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) 1 x 10^6 cells/kg in normal saline injection",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Low-dose UC-MSCs"
              ]
            }
          },
          {
            "ArmGroupLabel": "High-Dose UC-MSCs",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) 3 x 10^6 cells/kg in normal saline injection",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: High-dose UC-MSCs"
              ]
            }
          },
          {
            "ArmGroupLabel": "Methotrexate",
            "ArmGroupType": "Active Comparator",
            "ArmGroupDescription": "5-25mg Methotrexate orally",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Methotrexate"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "Low-dose UC-MSCs",
            "InterventionDescription": "Participants will receive 6 times UC-MSCs infusions (each time 1×10^6/kg). The first time to fourth time will be given once a week for successive 4 weeks（week 0,1,2,3）, then the last two times will be given once every two weeks（week 5,7）.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Low-Dose UC-MSCs"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "regenskin"
              ]
            }
          },
          {
            "InterventionType": "Biological",
            "InterventionName": "High-dose UC-MSCs",
            "InterventionDescription": "Participants will receive 6 times UC-MSCs infusions (each time 3×10^6/kg). The first time to fourth time will be given once a week for successive 4 weeks（week 0,1,2,3）, then the last two times will be given once every two weeks（week 5,7）.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "High-Dose UC-MSCs"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "regenskin"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Methotrexate",
            "InterventionDescription": "Participants will be administered Methotrexate (each time 5-25mg) orally once a week for successive 16 weeks(week 0-15).",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Methotrexate"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Proportion of subjects who have 75% or more reduction in [Psoriasis area-and-severity index score (PASI)] (PASI75) at week 20",
            "PrimaryOutcomeDescription": "The proportion of subjects who have a reduction of 75% or more from baseline in the psoriasis area-and-severity index score (PASI 75) at week 20",
            "PrimaryOutcomeTimeFrame": "Week 20"
          },
          {
            "PrimaryOutcomeMeasure": "Proportion of subjects who achieve a score of 0 or 1 on a 5-point Physician's global assessment（PGA0/1) at week 20",
            "PrimaryOutcomeDescription": "The proportion of subjects who achieve a score of 0（clear）or 1（almost clear）on a 5-point Physician's global assessment（PGA0/1) at week 20",
            "PrimaryOutcomeTimeFrame": "Week 20"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Proportion of subjects who have 90% or more reduction in [Psoriasis area-and-severity index score (PASI)] (PASI90) at week 20",
            "SecondaryOutcomeDescription": "The proportion of subjects who have a reduction of 90% or more from baseline in the psoriasis area-and-severity index score (PASI 90) at week 20",
            "SecondaryOutcomeTimeFrame": "Week 20"
          },
          {
            "SecondaryOutcomeMeasure": "Proportion of subjects who have 75% or more reduction in [Psoriasis area-and-severity index score (PASI)] (PASI75) at week 12,16,36,52",
            "SecondaryOutcomeDescription": "The proportion of subjects who have a reduction of 75% or more from baseline in the psoriasis area-and-severity index score (PASI 75) at week 12,16,36,52",
            "SecondaryOutcomeTimeFrame": "Week 12,16,36,52"
          },
          {
            "SecondaryOutcomeMeasure": "Proportion of subjects who achieve a score of 0 or 1 on a 5-point Physician's global assessment（PGA0/1) at week 12,16,36,52",
            "SecondaryOutcomeDescription": "The proportion of subjects who achieve a score of 0（clear）or 1（almost clear）on a 5-point Physician's global assessment（PGA0/1) at week 12,16,36,52",
            "SecondaryOutcomeTimeFrame": "Week 12,16,36,52"
          },
          {
            "SecondaryOutcomeMeasure": "Frequency of Adverse Events and Serious Adverse Events",
            "SecondaryOutcomeDescription": "Frequency of all Adverse Events (AEs) and Serious Adverse Events (SAEs) that occur during the whole trial including the observational period (AEs and SAEs include but not limited to headaches, allergies, fever and so on",
            "SecondaryOutcomeTimeFrame": "Week 0 through week 52"
          },
          {
            "SecondaryOutcomeMeasure": "Proportion of subjects who experience psoriasis relapse",
            "SecondaryOutcomeDescription": "The proportion of subjects who experience a psoriasis relapse at any time until week 52. Psoriasis relapse is defined as loss of > 50% of the initial PASI improvement measured at week 7",
            "SecondaryOutcomeTimeFrame": "Week 8 though week 52"
          }
        ]
      },
      "OtherOutcomeList": {
        "OtherOutcome": [
          {
            "OtherOutcomeMeasure": "Change from Baseline in Dermatology Life Quality Index (DLQI) score though 52 weeks",
            "OtherOutcomeDescription": "DLQI score will be assessed at week 0,1,2,3,5,7,12,16,20,36,52",
            "OtherOutcomeTimeFrame": "Week 0,1,2,3,5,7,12,16,20,36,52"
          },
          {
            "OtherOutcomeMeasure": "Exploring the theoretical basis of stem cell therapy for psoriasis",
            "OtherOutcomeDescription": "Analysis the serum cytokine content, immunological subgroup and pathological section to explore the theoretical basis of stem cell therapy for psoriasis",
            "OtherOutcomeTimeFrame": "0,1,2,3,5,7 12,16,20,36,52 week"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nMale or female patients ≥18 years old with moderate-to-severe psoriasis.\nDiagnosis of plaque psoriasis at least 6 months before entering the study.\nModerate-to-severe plaque psoriasis(PASI≥10，or BSA≥10% and DLQI score≥10).\nFailure after conventional therapy.\nNo other treatment for psoriasis during the period of the trial.\nWilling and able to comply with all study requirements and provide informed consent.\n\nExclusion Criteria:\n\nOther types of psoriasis,such as pustular, erythrodermic and guttate psoriasis).\nDrug-induced psoriasis (i.e., new onset or current exacerbation from beta-blockers, calcium channel inhibitors or lithium).\nOngoing use of other psoriasis treatments.\nEver use of any biologic drug directly targeting IL-17,IL-23,TNFa etc.\nActive systemic infections during the last two weeks (exception: common cold) prior to initiation of the trial and any infections that reoccur on a regular basis.\nHistory of malignancy .\nEvidence of infection with HIV, hepatitis B or hepatitis C.\nPregnant or lactating females, or willing to have a baby during the trial.\nCan not be traced on time.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "60 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Chunlei Zhang, doctor",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "86-13716014425",
            "CentralContactEMail": "zhangchunleius@163.com"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Chunlei Zhang, doctor",
            "OverallOfficialAffiliation": "Peking University Third Hospital",
            "OverallOfficialRole": "Study Chair"
          },
          {
            "OverallOfficialName": "Xin Guan, doctor",
            "OverallOfficialAffiliation": "Peking University Third Hospital",
            "OverallOfficialRole": "Principal Investigator"
          },
          {
            "OverallOfficialName": "Chunting Li, doctor",
            "OverallOfficialAffiliation": "Peking University Third Hospital",
            "OverallOfficialRole": "Principal Investigator"
          },
          {
            "OverallOfficialName": "Jinzhu Guo, doctor",
            "OverallOfficialAffiliation": "Peking University Third Hospital",
            "OverallOfficialRole": "Principal Investigator"
          },
          {
            "OverallOfficialName": "Wenhui Wang, doctor",
            "OverallOfficialAffiliation": "Peking University Third Hospital",
            "OverallOfficialRole": "Study Director"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Peking University Third Hospital",
            "LocationCity": "Beijing",
            "LocationCountry": "China",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Chunting Li, doctor",
                  "LocationContactRole": "Contact"
                }
              ]
            }
          },
          {
            "LocationFacility": "Tianjin Ever Union Biotechnology Co., Ltd.",
            "LocationCity": "Beijing",
            "LocationCountry": "China",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Zhengnan Li, master",
                  "LocationContactRole": "Contact"
                }
              ]
            }
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "No"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000011565",
            "ConditionMeshTerm": "Psoriasis"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000017444",
            "ConditionAncestorTerm": "Skin Diseases, Papulosquamous"
          },
          {
            "ConditionAncestorId": "D000012871",
            "ConditionAncestorTerm": "Skin Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M13574",
            "ConditionBrowseLeafName": "Psoriasis",
            "ConditionBrowseLeafAsFound": "Psoriasis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M14826",
            "ConditionBrowseLeafName": "Skin Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M18865",
            "ConditionBrowseLeafName": "Skin Diseases, Papulosquamous",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC17",
            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionMeshList": {
        "InterventionMesh": [
          {
            "InterventionMeshId": "D000008727",
            "InterventionMeshTerm": "Methotrexate"
          }
        ]
      },
      "InterventionAncestorList": {
        "InterventionAncestor": [
          {
            "InterventionAncestorId": "D000000020",
            "InterventionAncestorTerm": "Abortifacient Agents, Nonsteroidal"
          },
          {
            "InterventionAncestorId": "D000000019",
            "InterventionAncestorTerm": "Abortifacient Agents"
          },
          {
            "InterventionAncestorId": "D000012102",
            "InterventionAncestorTerm": "Reproductive Control Agents"
          },
          {
            "InterventionAncestorId": "D000045505",
            "InterventionAncestorTerm": "Physiological Effects of Drugs"
          },
          {
            "InterventionAncestorId": "D000000964",
            "InterventionAncestorTerm": "Antimetabolites, Antineoplastic"
          },
          {
            "InterventionAncestorId": "D000000963",
            "InterventionAncestorTerm": "Antimetabolites"
          },
          {
            "InterventionAncestorId": "D000045504",
            "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
          },
          {
            "InterventionAncestorId": "D000000970",
            "InterventionAncestorTerm": "Antineoplastic Agents"
          },
          {
            "InterventionAncestorId": "D000003879",
            "InterventionAncestorTerm": "Dermatologic Agents"
          },
          {
            "InterventionAncestorId": "D000004791",
            "InterventionAncestorTerm": "Enzyme Inhibitors"
          },
          {
            "InterventionAncestorId": "D000005493",
            "InterventionAncestorTerm": "Folic Acid Antagonists"
          },
          {
            "InterventionAncestorId": "D000007166",
            "InterventionAncestorTerm": "Immunosuppressive Agents"
          },
          {
            "InterventionAncestorId": "D000007155",
            "InterventionAncestorTerm": "Immunologic Factors"
          },
          {
            "InterventionAncestorId": "D000018501",
            "InterventionAncestorTerm": "Antirheumatic Agents"
          },
          {
            "InterventionAncestorId": "D000019384",
            "InterventionAncestorTerm": "Nucleic Acid Synthesis Inhibitors"
          }
        ]
      },
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M10855",
            "InterventionBrowseLeafName": "Methotrexate",
            "InterventionBrowseLeafAsFound": "Self-",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M3433",
            "InterventionBrowseLeafName": "Antimetabolites",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M6226",
            "InterventionBrowseLeafName": "Dermatologic Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M7770",
            "InterventionBrowseLeafName": "Folic Acid",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M16698",
            "InterventionBrowseLeafName": "Vitamin B Complex",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M7771",
            "InterventionBrowseLeafName": "Folic Acid Antagonists",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M9364",
            "InterventionBrowseLeafName": "Immunosuppressive Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M9353",
            "InterventionBrowseLeafName": "Immunologic Factors",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M19757",
            "InterventionBrowseLeafName": "Antirheumatic Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "T447",
            "InterventionBrowseLeafName": "Folinic Acid",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "T446",
            "InterventionBrowseLeafName": "Folic Acid",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "T448",
            "InterventionBrowseLeafName": "Folate",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "T475",
            "InterventionBrowseLeafName": "Vitamin B9",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "ANeo",
            "InterventionBrowseBranchName": "Antineoplastic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "ARhu",
            "InterventionBrowseBranchName": "Antirheumatic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "Derm",
            "InterventionBrowseBranchName": "Dermatologic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "Repr",
            "InterventionBrowseBranchName": "Reproductive Control Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          },
          {
            "InterventionBrowseBranchAbbrev": "Micro",
            "InterventionBrowseBranchName": "Micronutrients"
          },
          {
            "InterventionBrowseBranchAbbrev": "Hemat",
            "InterventionBrowseBranchName": "Hematinics"
          },
          {
            "InterventionBrowseBranchAbbrev": "Vi",
            "InterventionBrowseBranchName": "Vitamins"
          }
        ]
      }
    }
  }
}